Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
1985605-59-1
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developer |
gptkb:Vertex_Pharmaceuticals
gptkb:Merck_&_Co. |
| gptkbp:hasMolecularFormula |
C21H22N8O2S
|
| gptkbp:hasUNII |
6Q1K1Q1Q1F
|
| https://www.w3.org/2000/01/rdf-schema#label |
camonsertib
|
| gptkbp:indication |
gptkb:cancer
solid tumors |
| gptkbp:IUPACName |
N-(3-((2-(1H-tetrazol-5-yl)pyridin-4-yl)amino)phenyl)-4-(methylthio)pyrimidine-2-carboxamide
|
| gptkbp:mechanismOfAction |
ATR kinase inhibitor
|
| gptkbp:PubChem_CID |
CHEMBL4297596
121489553 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
ATR inhibitor M6620
M6620 VX-803 |
| gptkbp:bfsParent |
gptkb:Repare_Therapeutics
|
| gptkbp:bfsLayer |
7
|